ADMA Biologics' second quarter looked, at first glance, like a company that had hit a wall. Total revenue rose just 2% to $124.4 million, and the stock sits roughly 50% below its January high near $20 - a market verdict that says the immune globulin boom may be over. The second glance says the opposite. The flat headline conceals a quiet transformation in what ADMA actually sells: ASCENIV, the high-margin, premium-priced product, grew 24% to $102.9 million and now makes up roughly 83% of revenue, while the legacy BIVIGAM standard product - the one caught in the crossfire of aggressive new pricing in the IG market - fell 49% to $19.4 million. Because the mix shifted so sharply toward the premium product, gross margin jumped from 55% to 69% in a single year, and the company converted that into a 22% jump in adjusted EBITDA to $61.8 million and an 11% rise in GAAP net income to $37.8 million.
That combination - a nearly flat top line with sharply higher profit and accelerating demand for the product that carries the growth thesis - is the whole story of the quarter. Management says ASCENIV demand accelerated through the quarter, with June posting the strongest month-over-month utilization growth since the first half of 2024. It is signing up new prescribers, expanding pediatric use after an FDA label expansion, and pointing to new real-world data that it believes justify premium pricing. And it is spending the cash that follows: ADMA bought back roughly 7.1 million shares for $45 million in the quarter, or about $156 million in the first half, retiring what it says is 5.3% of its outstanding stock as of mid-2026. The stock trades near $9.91, about 8x forward EV/EBITDA on full-year guidance of $265–300 million - a price that looks already to have priced in the competitive gloom, while ASCENIV is compounding. The question the quarter poses is whether the flat revenue headline is a temporary pause or the new ceiling, and whether ASCENIV's growth can keep outrunning the pricing pressure that crushed BIVIGAM.